Log In
Print this Print this

Farydak, panobinostat (LBH589)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionOral pan-deacetylase (DAC) inhibitor
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today